One of the most precious metals has traditionally been valuable during rough economic times to protect wealth.
University of Southampton researchers in Southern England have experienced significant success using the precious metal in nanoparticle form against cancer. Small dosages of gold nanoparticles keep malignant tumors from sustaining themselves on blood and oxygen. The feeding process is known as angiogenesis.
"The peptide-functionalized gold nanoparticles that we synthesized are very effective in the deliberate activation or inhibition of angiogenic genes," stated physics lecturer Dr. Antonio Kanaras, research team leader. "We have found that gold nanoparticles can have a dual role in cellular manipulation. Applying laser irradiation, we can use the nanoparticles either to destroy endothelial cells, as a measure to cut the blood supply to tumors, or to deliberately open up the cellular membrane in order to deliver a drug efficiently."
Kanaras leads a team that thus far has seen two papers published regarding its work with angiogenesis. The team has submitted a third essay for publication. Through the remainder of 2011, researchers intend to submit four additional essays.
Employing nanotechnology for angiogenic manipulation is one significant researchers' goal.
This material is conveyed as a solicitation for entering into a derivatives transaction.
This material has been prepared by a Daniels Trading broker who provides research market commentary and trade recommendations as part of his or her solicitation for accounts and solicitation for trades; however, Daniels Trading does not maintain a research department as defined in CFTC Rule 1.71. Daniels Trading, its principals, brokers and employees may trade in derivatives for their own accounts or for the accounts of others. Due to various factors (such as risk tolerance, margin requirements, trading objectives, short term vs. long term strategies, technical vs. fundamental market analysis, and other factors) such trading may result in the initiation or liquidation of positions that are different from or contrary to the opinions and recommendations contained therein.
Past performance is not necessarily indicative of future performance. The risk of loss in trading futures contracts or commodity options can be substantial, and therefore investors should understand the risks involved in taking leveraged positions and must assume responsibility for the risks associated with such investments and for their results.
Trade recommendations and profit/loss calculations may not include commissions and fees. Please consult your broker for details based on your trading arrangement and commission setup.
You should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources. You should read the "risk disclosure" webpage accessed at www.DanielsTrading.com at the bottom of the homepage. Daniels Trading is not affiliated with nor does it endorse any third-party trading system, newsletter or other similar service. Daniels Trading does not guarantee or verify any performance claims made by such systems or service.